Full-Time

Senior Process Engineer

Vector Process Development and MS&T

Posted on 8/15/2024

Arcellx

Arcellx

201-500 employees

Develops immunotherapies for cell therapy

Compensation Overview

$135k - $155k/yr

+ Annual Bonus + Equity Grant

North Bethesda, MD, USA

Relocation assistance is offered if required.

Relocation assistance is offered if required.

Relocation assistance is offered if required.

Category
🧬Biology & Biotech (2)
,
Requirements
  • BS in chemical, biological, biomedical or biochemical engineering with 10+ yrs. of relevant experience, or MS and 8+ years of relevant experience, or Ph.D and 2+ years of relevant experience.
  • Strong engineering, scientific and operational background in implementation of bioprocess unit operations and aseptic cell culture.
  • Strong understanding of process development, technical transfer, and GMP requirements.
  • Experience with viral vector production processes and analytical characterization methods.
Responsibilities
  • Participate in technical transfers to CMOs and provide manufacturing science and technology support to ensure robust production in a GMP environment.
  • Lead manufacturing deviations investigations.
  • Critically analyze and trend process data.
  • Analyze laboratory experiments to support cell culture process development and GMP processes transfer activities to enable clinical manufacturing.
  • Engage with CMOs as the person-in-plant (PIP) and process SME.
  • Work with process and analytical development scientists for product characterization.
  • Review batch records, SOPs, raw material specifications, development reports and GMP protocols at Arcellx and CMOs.
  • Support the change control and the change management of different process versions and comparability assessments for process changes.
  • Travel up to 30% to engage with external partners and collaborators.

Arcellx develops immunotherapies aimed at transforming cell therapy for serious diseases. The company focuses on creating proprietary products that utilize advanced cell therapy techniques. Their approach involves extensive research and development to ensure the safety and effectiveness of their treatments. Arcellx differentiates itself from competitors by concentrating on unmet medical needs and forming partnerships and licensing agreements to support their commercialization efforts. The ultimate goal of Arcellx is to provide innovative treatment options for patients through successful regulatory approval and product sales.

Company Size

201-500

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Kite enhances Arcellx's multiple myeloma program development.
  • Recent clinical data shows robust long-term responses for CART-ddBCMA.
  • Advancements in gene editing could improve Arcellx's CAR-T product efficacy.

What critics are saying

  • Competition from Legend Biotech and Johnson & Johnson's Carvykti is significant.
  • High costs of CAR-T therapies may limit market adoption and accessibility.
  • Dependence on partnerships like Kite could pose strategic risks.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has Fast Track and Orphan Drug designations from the FDA.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced multiple myeloma cell targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

↓ -5%

1 year growth

↓ -1%

2 year growth

↓ -5%
Business Wire
May 21st, 2025
Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

Arcellx announces its participation at TD Cowen's 6th Annual Oncology Innovation Summit and its investor event During EHA2025.

Business Wire
Mar 20th, 2025
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors.

BioSpace
Feb 28th, 2025
Arcellx To Participate At The Td Cowen 45Th Annual Health Care Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible

Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

INACTIVE